Gelonghui, September 11 | Jinkai Shengke (301509.SZ) said at an investor relations event that the company has made active adjustments and the main countermeasures include: 1. Strengthen the strength of the BD team, give full play to the advantages of the international BD team and customer resources, focus on developing customers in Europe and the Asia-Pacific region, and actively expand business growth on the basis of seeking project orders from existing customers; 2. Give full play to the strategic support role of the US GMP production base and R&D center to make performance contributions and introduce more projects as soon as possible while hedging risks; 3. Sufficient Give full play to the advantages of fluorination technology in the pharmaceutical CDMO field, based on the company's fluorination specialty technology, appropriately allocate production capacity to obtain orders from the non-pharmaceutical sector in the short to medium term, and seek new growth points in the field of special fluorinated chemicals; 4. Strengthen R&D investment and R&D team building, strengthen process optimization and technical reserves for the company's specialty products to control and reduce project costs, and carry out some laboratory services in conjunction with project introduction. The above response adjustments are based on the long-term development of the company, and it is hoped that the company's performance can be stabilized and gradually broken out of the trough as soon as possible.